Atlas Trials

The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Clinical trial NCT06176911 · UNKNOWN

Trial details

NCT number
NCT06176911
Sponsor
Peking University People's Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Immune Thrombocytopenia
Start date
2023-12-05
Primary completion
2024-12-30
Enrollment
124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.